BMO Capital Initiates Coverage on 7 Biotech Stocks: Outperform Ratings for ALNY, ASND, BMRN & More
BMO Capital starts coverage on ALNY, ASND, BMRN, CATX & more with Outperform ratings and price targets. See full analyst insights and targets.
/ 131 items
#XY Analyst Up/Down↓
From Moderna to Sellas: The Next Major Catalyst in Cancer Vaccines
Sellas GPS data is imminent, Maxim keeps Buy/$30 PT. BNTX also in focus.
Wells Fargo and Stifel Flag Beneficiaries of Moderna-Merck Cancer Vaccine Data
Wells Fargo and Stifel say Moderna and Merck's Phase 3 cancer vaccine data could benefit Repligen, Danaher, Thermo Fisher, and Maravai LifeSciences. TEM stock is also surging.
BMO Capital Bullish on Prime Medicine: Outperform Rating, $9 Target, and 2027 Clinical Catalysts
BMO cited Prime Medicine's unique prime-editing technology, which enables precise DNA corrections without creating double-strand breaks.
Analysts Initiate Coverage on Scribe Therapeutics with Price Targets Up to $60 as CRISPR Platform Gains Traction
Multiple firms initiate coverage on Scribe Therapeutics with Buy ratings and targets up to $60 after its IPO, spotlighting CRISPR tech for cholesterol.
Nuvation Bio: JPMorgan Sees Strong Ibtrozi Launch and Pipeline Upside
JPMorgan initiates Nuvation Bio at Overweight with $13 target, citing durable first-line adoption of Ibtrozi in ROS1+ lung cancer.